Results 141 to 150 of about 1,486,387 (308)

Transfemoral Transcatheter Aortic Valve Implantation (TF‐TAVI) for Patients With Left Ventricular Assist Device (LVAD) and Aortic Regurgitation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Aortic regurgitation (AR) develops in up to 25%−30% of patients with left ventricular assist device (LVAD). Treatment remains challenging since surgery confers significant peri‐operative risk and the lack of valvular calcification renders transfemoral transcatheter aortic valve implantation (TF‐TAVI) with non‐dedicated devices technically ...
Daniel Tai‐Leung Chan   +9 more
wiley   +1 more source

Nonsteroidal Anti‐Inflammatory Drugs as Modulators of Cation Channels: Fenamates Repurposing in Channelopathies

open access: yesChemMedChem, EarlyView.
Beyond their established role as nonsteroidal anti‐inflammatory drugs (NSAIDs), fenamates (niflumic, flufenamic, mefenamic, meclofenamic, and tolfenamic acids) have recently been identified as modulators of cationic ion channels. This review highlights their differential effects on ion channel activity and explores their potential for repurposing in ...
Paola Laghetti   +4 more
wiley   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu   +21 more
wiley   +1 more source

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum   +10 more
wiley   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel   +13 more
wiley   +1 more source

Arrhythmias: Cardiac resynchronization therapy in women

open access: yesNature Reviews Cardiology, 2014
D. Narasimha, A. Curtis
semanticscholar   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray   +2 more
wiley   +1 more source

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai   +2 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy